Response Genetics, Inc. (RGDX) Signs Agreement with GlaxoSmithKline
Response Genetics Inc. is a company focused on the development and sale of molecular diagnostic tests for cancer which are based on its proprietary and patented technologies. The company's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. The company announced recently that it has signed a non-exclusive agreement with global drug giant GlaxoSmithKline. Under the terms of the agreement, Glaxo gains certain rights to Response Genetics' proprietary PCR (polymerase chain reaction) analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. Specific genetic mutations…